Please login to the form below

Not currently logged in
Email:
Password:

Janssen boosts vaccines pipeline with GlycoVaxyn deal

Research will focus on targeting multiple bacterial pathogens

Janssen has agreed a deal with Swiss vaccines specialist GlycoVaxyn to research and develop a vaccine for multiple bacterial pathogens.

Its early development will see GlycoVaxyn collaborate with Janssen's vaccines- focused affiliate Crucell, but once the programme enters later-stage clinical studies, Janssen will take over development and then lead commercialisation of any product that gains approval.

The partners' research efforts will make use of GlycoVaxyn's bio-conjugation technology, which is designed to support the development of polyvalent conjugate vaccines – a form of vaccine that can be used to protect against multiple targets.

GlycoVaxyn's co-founder and chief scientific officer Michael Wacker said the technology “should make the development and commercialisation of these vaccines more feasible and reliable”.

Financial details of the deal were not disclosed, although GlycoVaxyn will receive an upfront and milestone payments, plus reimbursement of R&D expenses and royalties on future sales.

The announcement comes just weeks after GlycoVaxyn signed another big pharma deal, tying up with GSK to collaborate on the development of anti-bacterial conjugate vaccines.

As with the Janssen deal, financial terms were not disclosed, nor the specific type of infection to be targeted.

The two deals in quick succession demonstrate a wider faith in GlycoVaxyn's bio-conjugate vaccine platform, and the company's CEO Philippe Dro welcomed the latest agreement.

He said: “This collaboration is a further confirmation of the position GlycoVaxyn is about to occupy in the vaccine development space.

“The whole team is dedicated to establish GlycoVaxyn's technology as a powerful platform able to generate innovative vaccine candidates.”

8th January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics